Last reviewed · How we verify
RO4917838 and Rosuvastatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
RO4917838 and Rosuvastatin (RO4917838 and Rosuvastatin) — Hoffmann-La Roche.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RO4917838 and Rosuvastatin TARGET | RO4917838 and Rosuvastatin | Hoffmann-La Roche | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RO4917838 and Rosuvastatin CI watch — RSS
- RO4917838 and Rosuvastatin CI watch — Atom
- RO4917838 and Rosuvastatin CI watch — JSON
- RO4917838 and Rosuvastatin alone — RSS
Cite this brief
Drug Landscape (2026). RO4917838 and Rosuvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/ro4917838-and-rosuvastatin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab